BioSpace News Archive

Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2023 financial results.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2023.

ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Series C Financing.

Aura Biosciences Inc. today reported financial results for the second quarter ended June 30, 2023, and provided clinical development and operational highlights.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on operational progress for the second quarter and six months ended June 30, 2023.

Elite Pharmaceuticals, Inc. announced today that the first quarter financial results of the 2024 fiscal year will be released on Monday, August 14, 2023.

Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 9th of August that an Investigational New Drug (IND) application has been approved by the Ministry of Food and Drug Safety (MFDS) for mRNA vaccine LEM-mR203 with its nano-drug delivery technology, DegradaBALL ® on 21st of July.

Century Therapeutics, Inc. today reported financial results and business highlights for the second quarter ended June 30, 2023.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. today announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4.00 per share of Decibel common stock payable in cash at closing.

Eyenovia, Inc. today announced management will deliver a presentation and participate in a panel discussion at the H.C. Wainwright 3rd Annual Ophthalmology Day, which is taking place virtually on August 16, 2023.